Treatment of chronic constipation with colchicine: Randomized, double-blind, placebo-controlled, crossover trial
Treatment of chronic constipation with colchicine: Randomized, double-blind, placebo-controlled, crossover trial
复制标题
DOI：
10.1016/s0002-9270(03)00135-7
复制
发表时间：
2003-05-01
影响因子：
9.8
通讯作者：
Sninksy, CA
中科院分区：
文献类型：
--
作者：
Verne, GN;Davis, RH;Sninksy, CA
目的：顽固性便秘是医生在所有实践环境中常见的胃肠道疾病。我们之前已经证明 p.d.在一项为期 8 周的开放标签治疗试验中，秋水仙碱（0.6 mg tid）可增加慢性便秘患者的自发排便次数、加速胃肠道转运并改善胃肠道症状。这项研究的目的是确定 p.d. 是否可以。在一项随机、安慰剂对照、交叉试验中，秋水仙碱会增加特发性慢性便秘患者的自发排便并加速结肠传输。 方法：共有 16 名患有慢性特发性便秘且对标准药物治疗无效的患者（15 名女性，1 名男性），平均年龄 47 岁（年龄范围 25-89 岁）参与了这项研究。患者随机接受口服秋水仙碱 0.6 mg 或口服。 t.i.d.或相同的安慰剂邮政信箱t.i.d.以双盲、交叉方式进行总共 4 周。患者记录每日排便次数以及每日恶心、腹痛和腹胀的症状。在基线、第 6 周和第 12 周计算平均结肠传输。结果：与基线和安慰剂条件相比，秋水仙碱增加了排便次数并加速了结肠传输。恶心和腹胀的评分在不同条件下没有显着差异。在秋水仙碱给药期间，平均腹痛大于基线或安慰剂条件，但是，到患者服用秋水仙碱的最后一周，疼痛显着减轻。结论：秋水仙碱增加了慢性便秘患者的排便频率并加速了结肠运输。秋水仙碱可能是一种有效的药物，可供医生用来治疗对标准药物治疗无效的慢性便秘患者。 (C) 2003 年，作者：Am。科尔。胃肠病学。
OBJECTIVE: Refractory constipation is a common GI complaint seen by physicians in all practice settings. We have previously shown that p.d. colchicine (0.6 mg t.i.d.) increases the number of spontaneous bowel movements, hastens GI transit, and improves GI symptoms in patients with chronic constipation during an 8-wk, open-label therapeutic trial. The aim of this study was to determine if p.d. colchicine will increase spontaneous bowel movements and accelerate colonic transit in patients with idiopathic chronic constipation in a randomized, placebo-controlled, crossover trial.METHODS: A total of 16 patients (15 women, one man) with a mean age of 47 yr (age range 25-89) with chronic idiopathic constipation who were refractory to standard medical therapy participated in the study. Patients randomly received either colchicine 0.6 mg p.o. t.i.d. or an identical placebo p.o. t.i.d. for a total of 4 wk in a double-blind, crossover fashion. Patients recorded their daily number of bowel movements and daily symptoms of daily nausea, abdominal pain, and bloating. Mean colonic transit was calculated at baseline, weeks 6 and 12.RESULTS: Colchicine increased the number of bowel movements and accelerated colonic transit compared with baseline and placebo conditions. There were no significant differences between conditions on ratings of nausea and bloating. During colchicine administration, mean abdominal pain was greater than the baseline or placebo conditions, however, the pain decreased significantly by the last week the patient was on colchicine.CONCLUSION: Colchicine increases the frequency of bowel movements and hastens colonic transit in patients with chronic constipation. Colchicine may be an effective agent available to practitioners to treat a subset of patients with chronic constipation who are refractory to standard medical therapy. (C) 2003 by Am. Coll. of Gastroenterology.